We will keep you updated
The latest from Median
Business Intelligence-based reporting optimizes the operational efficiency of clinical trial imaging services
iBiopsy® AI-powered software for lung cancer screening deployment at scale. Empowering radiologists for swift & accurate diagnosis
New results, obtained on a very large cohort of 9,863 patients show drastically improved performance of the iBiopsy® LCS CADe/CADx Software as Medical Device (SaMD) with a sensitivity of 96.5% at a specificity of 97.2%.
urther to the Q-submission phase completion, Median’s iBiopsy® LCS CADe/CADx SaMD pivotal study protocols are now finalized and ready for study execution.
Our webinar replay is available here: Decentralized Clinical Trials: The patient-centric future of oncology R&D?
Watch our video: iCRO Imaging Services for Clinical Trials in Oncology
Watch our video: iBiopsy®, enhancing imaging diagnostic accuracy
ConferencesMay 3-4, 2023
Outsourcing In Clinical Trials Europe 2023
Decentralized Clinical Trials: The patient-centric future of oncology R&D?
Full or Hybrid DCT? What is the best fit when it comes to oncology research, the role of clinical trial imaging with these models, and how do you ensure success? Watch this webinar replay to gain insight into DCT strategies and tools to consider for your next oncology trial.